TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22607134
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (prednisone, azathioprine, and NAC)
Study: 7475138
Drug: Acadesine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acadesine (0.1 mg/kg per minute intravenous infusion over 7 hours, 5 micrograms/ml in cardioplegic solution)
Study: 28138133
Drug: Baseline thyroid
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline thyroid hormones
Study: 19121589
Drug: Oral anti-vitamin-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-vitamin-K agents (AVK)
Study: 19121589
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) in patients with cancer
Study: 19121589
Drug: Oral anti-vitamin-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-vitamin-K agents (AVK) in patients with cancer
Study: 17966026
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg preoperatively and then twice daily)
Study: 11465636
Drug: Fluoxetine (n=27)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (n=27)
Study: 9220235
Drug: 0.15% ganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% ganciclovir gel
Study: 9220235
Drug: 0.05% ganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% ganciclovir gel
Study: 8285927
Drug: Nifedipine 60
Normalized name: nifedipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 60 mg/d
Study: 2821790
Drug: Bromodeoxyuridine (BUdR)
Normalized name: Bromodeoxyuridine
DrugBank: Broxuridine (DB12028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromodeoxyuridine (BUdR) or iododeoxyuridine (IUdR) during high-dose brain irradiation (total radiation dose 65-70 Gy)
Study: 2821790
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who completed planned treatment (48 patients)
Study: 2821790
Drug: BUdR versus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUdR versus IUdR, 12-h versus 24-h infusion schedule, degree of surgical resection, or sex
Study: 30902613
Drug: Alectinib, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib, 600 mg twice daily
Study: 30902613
Drug: Crizotinib, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib, 250 mg
Study: 25457735
Drug: Iodixanol 270
Normalized name: IODIXANOL 270mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 270 (270 mg I/mL), scanned using low tube voltage of 80 kVp, reconstructed with iterative reconstruction techniques (IRT)
Study: 25457735
Drug: Iopromide 370
Normalized name: IOPROMIDE 370mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide 370 (370 mg I/mL), scanned using 100 kVp, reconstructed with filtered back projection
Study: 22000927
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of PYY(3-36) and GLP-1(7-36 amide)
Study: 19891258
Drug: GaAIAS (780
Approvals — FDA: no, EMA: no, PMDA: no
Description: GaAIAS (780 nm) laser, applied in continuous mode, twice a week, for four weeks, with energy set to 25 J/cm2.
Study: 19891258
Drug: GaAIAS (780
Approvals — FDA: no, EMA: no, PMDA: no
Description: GaAIAS (780 nm) laser, applied in continuous mode, twice a week, for four weeks, with energy set to 60 J/cm2.
Study: 19891258
Drug: GaAIAS (780
Approvals — FDA: no, EMA: no, PMDA: no
Description: GaAIAS (780 nm) laser, applied in continuous mode, twice a week, for four weeks, with energy set to 105 J/cm2.
Study: 16489525
Drug: Capsaicin infusion
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin infusion (40 microg/ml, 2.5 ml/min for 60 minutes)
Study: 15486846
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (VAQTA; Merck), administered at weeks 0 and 24
Study: 6365849
Drug: Riboflavin supplement
Normalized name: Riboflavin supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin supplement (15 mg)
Study: 17275926
Drug: Sucralfate (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1g solution, swished and swallowed four times daily for 7 days)
Study: 17275926
Drug: Lactulose (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (1g solution, swished and swallowed four times daily for 7 days)
Study: 10344012
Drug: Antioxidant therapy;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy; specific details on dosage and duration not available
Study: 7562419
Drug: Erythropoietin (Epo)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (Epo) 10 U/kg i.v. bolus dose
Study: 7562419
Drug: Erythropoietin (Epo)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (Epo) 100 U/kg i.v. bolus dose
Study: 7562419
Drug: Erythropoietin (Epo)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (Epo) 500 U/kg i.v. bolus dose
Study: 30205241
Drug: Dietary sodium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary sodium reduction to <1500 mg daily counseling
Study: 18551008
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate controlled 12 week exercise program (arm-cycling at target lactate concentrations of 2.0 +/- 0.5 mmol/l)
Study: 15786889
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) with TST screening
Study: 15786889
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) without TST screening
Study: 31714586
Drug: MK-2206 200
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 200 mg weekly (initial dose), reduced to 135 mg due to toxicity
Study: 31270967
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron administration
Study: 27392481
Drug: CM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM plus WM therapy (Reduning Injection or Xiyanping Injection)
Study: 27392481
Drug: WM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WM therapy alone
Study: 22297674
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg elemental calcium diet
Study: 22297674
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg elemental calcium diet
Study: 11346139
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate-based triple therapy (RAM group)
Study: 11346139
Drug: Omeprazole-based triple
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole-based triple therapy (OAM group)
Study: 15258452
Drug: 3% ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% ascorbic acid cream
Study: 9076466
Drug: Pre-operative blood
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative blood haemoglobin concentration in the range of 100-129 g/l
Study: 9076466
Drug: Adjusted for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted for impaired health status and age > or = 75 years, fluid absorption > or = 500 ml, and blood loss > or = 275 ml
Study: 8419003
Drug: Indobufen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (100 mg b.i.d.)
Study: 19364302
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg once daily
Study: 15464786
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg) and Vitamin E (400 IU)
Study: 31937352
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day krill oil
Study: 16500491
Drug: ivMCE (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivMCE (intravenous myocardial contrast echocardiography)
Study: 12404073
Drug: Heroin (491
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin (491 mg average daily dose, n=17)
Study: 12404073
Drug: Morphine (597
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (597 mg average daily dose, n=16)
Study: 10846637
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (drug intake every day for the whole experimental period)
Study: 9160923
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg twice daily for 2 weeks
Study: 24358760
Drug: Improved central
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved central venous catheter indwelling of intraperitoneal drainage, irrigation, cavity injection, combined with systemic comprehensive treatment
Study: 28038680
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (CYC) for 1 year followed by 1 year of placebo
Study: 24998644
Drug: Vaccine-induced inflammation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-induced inflammation (typhoid vaccination)
Study: 8840384
Drug: Single-ingredient supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-ingredient supplements
Study: 1427586
Drug: Omeprazole 30
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 30 mg/day
Study: 12702130
Drug: HIV‐1 rgp160
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐1 rgp160 vaccine
Study: 26870801
Drug: Tetanus vaccine
Normalized name: Tetanus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus vaccine
Study: 12702130
Drug: Tetanus vaccine
Normalized name: Tetanus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus vaccine (Control group)
Study: 10233027
Drug: Estradiol-17beta (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol-17beta (1 mg micronized steroid twice daily orally)
Study: 28024819
Drug: Lava C.O.S.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lava C.O.S. CAD software and centralized CAM (group L)
Study: 12229073
Drug: Tracking procedures
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tracking procedures used in Project Towards No Drug Abuse (Project TND)
Study: 31238912
Drug: Reduced-dosage ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dosage ketoprofen (0.5 mg/kg SC once; 0.25 mg/kg PO daily)
Study: 31238912
Drug: Reduced-dosage ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dosage ketoprofen (0.5 mg/kg SC once; 0.25 mg/kg PO daily) + tramadol (5 mg/kg/day PO)
Study: 31238912
Drug: Standard-dosage ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dosage ketoprofen (2 mg/kg SC, then 1 mg/kg PO daily)
Study: 21606427
Drug: Fluorouracil (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil (225 mg/m(2)/d) plus pelvic radiation (50.4 Gy in 28 daily fractions)
Study: 21606427
Drug: Fluorouracil (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil (225 mg/m(2)/d) plus pelvic radiation (50.4 Gy in 28 daily fractions) and oxaliplatin (60 mg/m(2) weekly × 6)
Study: 19138610
Drug: Superior joint
Normalized name: Astaxanthin/Hyaluronic Acid/Krill Oil Oral Capsule, Liquid Filled [MEGARED SUPERIOR JOINT CARE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superior joint space injections of sodium hyaluronate
Study: 19138610
Drug: Inferior joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inferior joint space injections of sodium hyaluronate
Study: 15582012
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of dried ethanolic extract of guarana (approx 12% caffeine)
Study: 15582012
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of Panax ginseng (G115)
Study: 15582012
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 75 mg guarana and 200 mg Panax ginseng
Study: 11328420
Drug: Postoperative intravesical
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative intravesical instillation of mitomycin C (20 mg) and cytosine arabinoside (200 mg) 28 times over 2 years
Study: 12188443
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg/day
Study: 12188443
Drug: Benzbromarone 100
Normalized name: benzbromarone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone 100 mg/day
Study: 9849314
Drug: Allopurinol 450
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 450 to 600 mg/day
Study: 9849314
Drug: Benzbromarone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone (mean final dose 76 mg/day)
Study: 12883589
Drug: Ranitidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 600 mg
Study: 7986969
Drug: Ranitidine 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 1200 mg
Study: 2722308
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 450 mg 3‐sn‐polyenyl‐phosphatidylcholine (PPC)
Study: 25332469
Drug: Calcium (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (100 mg/test meal)
Study: 25332469
Drug: Calcium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (200 mg/test meal)
Study: 25332469
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) at 42.5 mg/test meal
Study: 25332469
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) at 85 mg/test meal
Study: 23895132
Drug: Kaempferol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaempferol (150 mg/kg)
Study: 23895132
Drug: Kaempferol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaempferol (30 mg/kg)
Study: 23895132
Drug: Fenofibrate (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (12 mg/kg)
Study: 18166838
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2 once every 3 weeks)
Study: 18166838
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 once every 3 weeks)
Study: 6256423
Drug: Theophylline (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (therapeutic doses given intravenously and orally over 3 days)
Study: 25712577
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg of misoprostol (n = 30)
Study: 25712577
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of dinoprostone (n = 30)
Study: 17414237
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (15‐mg patch, 4‐mg gum, and/or 10‐mg inhaler)
Study: 12410126
Drug: Inhibitor of
Normalized name: Membrane inhibitor of reactive lysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitor of specific tyrosine kinase
Study: 9857531
Drug: Sera containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sera containing specific antibodies for Staphylococcus aureus and Escherichia coli obtained from immunized rabbits
Study: 9857531
Drug: Autologous bacterial
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bacterial strains incubated with asthmatic patients' sera collected after autovaccines treatment
Study: 9857531
Drug: Anti-IgE antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-IgE antibodies
Study: 43650
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural block followed by intravenous prenalterol administration prior to induction of general anaesthesia
Study: 43650
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no specific treatment prior to general anaesthesia)
Study: 29879249
Drug: Topical oxymetazoline
Normalized name: oxymetazoline Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxymetazoline cream 1.0%
Study: 27007800
Drug: Gabapentin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600 mg preoperatively, one hour prior to surgery)
Study: 22768902
Drug: Olibra™ fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olibra™ fat emulsion (2.1 g twice daily)
Study: 22768902
Drug: Placebo (1.95
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.95 g milk fat, twice daily)
Study: 19417772
Drug: Moderate-intensity programme
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity programme with physician meetings, physical activity prescriptions, group counselling and bicycles
Study: 17495770
Drug: ProDisc-L (Synthes
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProDisc-L (Synthes Spine) lumbar total disc replacement
Study: 7988250
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) - 400 mg/m2 of cyclophosphamide, 40 mg/m2 of doxorubicin, and 60 mg/m2 of cisplatin, administered in four courses at 3-week intervals starting 30 days post-surgery.
Study: 2660374
Drug: Tablets with
Normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets with normal particle size
Study: 2660374
Drug: Tablets with
Normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets with coarse particle size
Study: 4600903
Drug: Idoxuridine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idoxuridine 5% in 100% dimethyl sulphoxide (DMSO), applied four-hourly for four days
Study: 4600903
Drug: Idoxuridine 25%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idoxuridine 25%, applied two-hourly
Study: 31804851
Drug: Insulin Aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Aspart Biosimilar SAR341402 (SAR‐Asp)
Study: 31804851
Drug: Originator Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Originator Insulin Aspart (NN‐Asp)
Study: 23635731
Drug: Bazedoxifene 20
Normalized name: bazedoxifene 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 20 mg and conjugated estrogens 0.45 mg
Study: 23635731
Drug: Bazedoxifene 20
Normalized name: bazedoxifene 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 20 mg and conjugated estrogens 0.625 mg
Study: 23635731
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens 0.45 mg and medroxyprogesterone acetate 1.5 mg
Study: 16792584
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) for 3 years
Study: 16120066
Drug: Indinavir pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir pharmacokinetics
Study: 9110067
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir maintenance
Study: 1937663
Drug: Unfiltered boiled
Normalized name: BOIL-EASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfiltered boiled coffee (caffeine content 860 mg/l)
Study: 1937663
Drug: Boiled-and-filtered coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boiled-and-filtered coffee (caffeine content 887 mg/l)
Study: 22845421
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MI) session before periodontal treatment
Study: 19201327
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no enamel treatment)
Study: 17484067
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg for 3 days)
Study: 11799306
Drug: Rhubarb-sage cream
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb-sage cream (23 mg/g rhubarb extract, 23 mg/g sage extract)
Study: 11799306
Drug: Sage cream
Normalized name: ARTEMISIA ARGYI LEAF 0.38 g in 100 mL TOPICAL CREAM [GONGFUTOUTANG Head massage cream]
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sage cream (23 mg/g sage extract)
Study: 11799306
Drug: Zovirax cream
Normalized name: acyclovir Topical Cream [Zovirax]
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zovirax cream (50 mg/g aciclovir)
Study: 11799306
Drug: Zovirax cream
Normalized name: acyclovir Topical Cream [Zovirax]
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zovirax cream
Study: 11799306
Drug: Rhubarb-sage cream
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb-sage cream
Study: 7919069
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR 2 - 3)
Study: 28331003
Drug: Taselisib 3-16
Normalized name: Taselisib
DrugBank: Taselisib (DB12108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taselisib 3-16 mg once-daily capsule
Study: 28331003
Drug: Taselisib 12
Normalized name: Taselisib
DrugBank: Taselisib (DB12108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taselisib 12 mg
Study: 28331003
Drug: Taselisib (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taselisib (any dose)
Study: 23945571
Drug: IM gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM gentamicin OD and oral amoxicillin twice daily for 7 days